What is IGF-1 LR3 and how does the Arg3 substitution reduce IGFBP binding?

IGF-1 LR3 (Long R3 IGF-1) is an 83-amino acid synthetic analog of human IGF-1 (Insulin-like Growth Factor-1) engineered with two critical modifications: (1) Glutamic acid→Arginine substitution at position 3 (E3R mutation, hence 'R3' designation), and (2) 13-amino acid N-terminal extension. These modifications fundamentally alter IGF binding protein (IGFBP) interactions while preserving IGF-1 receptor (IGF-1R) binding and signaling. Native IGF-1 (70 amino acids) binds IGFBPs with high affinity - IGFBPs act as carrier proteins sequestering >99% of circulating IGF-1, restricting bioavailability and creating extremely short half-life (~10 minutes free IGF-1, though IGFBP-bound complexes circulate longer). The Arg3 substitution disrupts critical IGFBP binding epitopes: position 3 glutamic acid in native IGF-1 forms salt bridge interactions with IGFBPs; replacing with positively-charged arginine eliminates these contacts reducing IGFBP affinity 100-1000 fold depending on IGFBP type. The N-terminal extension (adding 13 amino acids to the standard 70-AA IGF-1 structure creating 83-AA LR3 variant) provides steric hindrance further preventing IGFBP association. Consequences: (1) Reduced IGFBP binding dramatically increases free bioavailable IGF-1 LR3 vs native IGF-1 where most is sequestered. (2) Extended half-life - free IGF-1 LR3 circulates 20-30 hours vs native IGF-1's 10-minute free half-life, enabling sustained IGF-1R activation from single dose. (3) Enhanced IGF-1R signaling - more free peptide available to bind IGF-1R triggering PI3K-AKT-mTOR and MAPK pathways stimulating protein synthesis, cell proliferation, differentiation, and survival. (4) Tissue penetration - reduced IGFBP sequestration allows IGF-1 LR3 to access tissues more readily. Research applications include IGF-1 receptor pharmacology, IGFBP biology (comparing native IGF-1 vs LR3 reveals IGFBP regulatory roles), muscle growth mechanisms (myoblast proliferation/differentiation, protein synthesis, mTOR activation), extended-action IGF-1 analog development, comparative growth factor studies, and dissecting IGFBP vs IGF-1R contributions to IGF-1 physiology. The reduced IGFBP binding makes IGF-1 LR3 a potent research tool for sustained IGF-1R activation without IGFBP interference.

How does IGF-1 LR3 compare to native IGF-1 in receptor activation and bioavailability?

IGF-1 LR3 and native IGF-1 share the same receptor (IGF-1R) and activate identical downstream pathways, but differ dramatically in pharmacokinetics and bioavailability: (1) IGF-1R binding - both bind IGF-1R with high affinity (low nanomolar Kd) triggering receptor autophosphorylation and activation of PI3K-AKT-mTOR (protein synthesis, cell survival) and RAS-MAPK (proliferation) pathways; IGF-1 LR3 may show slightly reduced IGF-1R affinity vs native IGF-1 due to structural modifications, but this is offset by dramatically increased bioavailability. (2) IGFBP binding - native IGF-1 binds IGFBPs (especially IGFBP-3) with high affinity; >99% circulating IGF-1 is IGFBP-bound creating depot that slowly releases free IGF-1; IGF-1 LR3's Arg3 substitution and N-terminal extension reduce IGFBP binding 100-1000 fold leaving most IGF-1 LR3 in free bioavailable form. (3) Half-life - free native IGF-1: ~10 minutes (rapid degradation/clearance); IGFBP-bound IGF-1 complexes: hours (but unavailable for receptor binding); IGF-1 LR3: 20-30 hours as free peptide providing sustained IGF-1R activation. (4) Bioavailability - native IGF-1's high IGFBP binding creates only ~1% free bioavailable peptide; IGF-1 LR3's reduced IGFBP affinity produces >80% free form, yielding effectively 80-100x higher bioavailability at equivalent doses. (5) Tissue distribution - IGFBP sequestration restricts native IGF-1 tissue penetration; IGF-1 LR3's freedom from IGFBPs enables better tissue access. (6) Signaling duration - native IGF-1 produces transient IGF-1R activation (minutes) due to rapid clearance and IGFBP buffering; IGF-1 LR3 sustains receptor signaling over 24+ hours. (7) Research applications - native IGF-1 ideal for physiological IGF-1 biology and IGFBP interaction studies; IGF-1 LR3 preferred for sustained IGF-1R activation research, muscle growth studies, and pharmaceutical modeling of long-acting IGF-1 analogs. Choose native IGF-1 to study physiological IGF-IGFBP systems; choose IGF-1 LR3 for maximal sustained IGF-1R stimulation without IGFBP interference revealing pure receptor-mediated effects.

What purity and quality standards does your IGF-1 LR3 meet?

Our IGF-1 LR3 exceeds >98% purity verified by HPLC with comprehensive quality control for this 83-amino acid modified growth factor. Each batch undergoes: reverse-phase HPLC demonstrating >98% purity with retention time characteristic of the extended 83-AA LR3 analog, mass spectrometry molecular weight confirmation for the modified IGF-1 structure (expected mass ~9117 Da for the 83-amino acid LR3 variant vs ~7649 Da for native 70-AA IGF-1), peptide sequence verification confirming the 13-amino acid N-terminal extension plus glutamic acid→arginine substitution at position 3 via MS/MS fragmentation or Edman degradation, modification validation ensuring proper Arg3 incorporation and N-terminal extension accuracy, IGF-1 receptor binding bioassays measuring IGF-1 LR3's affinity for IGF-1R using receptor competition assays or cell-based binding studies (Kd typically low nanomolar, comparable to native IGF-1 despite structural modifications), IGFBP binding assays demonstrating reduced affinity - comparing IGF-1 LR3 vs native IGF-1 binding to IGFBP-3 and other IGFBPs via surface plasmon resonance or competition assays confirming 100-1000 fold reduction validating the Arg3/extension modifications, cell proliferation bioassays using myoblasts, fibroblasts, or other IGF-1-responsive cells measuring dose-dependent proliferation (MTT/BrdU assays) demonstrating functional IGF-1R activation, AKT and MAPK phosphorylation assays - treating cells with IGF-1 LR3 and measuring pAKT (Ser473) and pERK1/2 via Western blot confirming PI3K-AKT-mTOR and RAS-MAPK pathway activation, protein synthesis assays using [3H]-leucine incorporation or puromycin incorporation measuring IGF-1 LR3-stimulated translation validating anabolic signaling, endotoxin testing ( 98% purity ensures reproducible IGF-1R activation, consistent proliferative/anabolic responses, and reliable muscle growth research. Quality control validates chemical identity (83-AA sequence with Arg3 and N-terminal extension), reduced IGFBP binding (key functional modification), and biological activity (IGF-1R signaling, cell proliferation, protein synthesis) essential for IGF-1 analog research.

What research applications benefit from IGF-1 LR3's extended bioavailability?

IGF-1 LR3 excels in research requiring sustained IGF-1R activation without IGFBP interference: IGF-1 receptor pharmacology investigating receptor binding kinetics, autophosphorylation, PI3K-AKT-mTOR signaling (protein synthesis, cell survival), and RAS-MAPK pathway activation (proliferation) with extended timecourse vs native IGF-1's transient effects; muscle growth mechanisms examining myoblast proliferation and differentiation into myotubes, satellite cell activation and fusion, protein synthesis regulation via mTOR-p70S6K-4E-BP1 axis, and myofibrillar protein accretion - IGF-1 LR3's sustained signaling reveals chronic IGF-1R stimulation effects on muscle hypertrophy; IGFBP biology research comparing native IGF-1 (high IGFBP binding) vs IGF-1 LR3 (minimal IGFBP binding) to dissect IGFBP regulatory roles - revealing whether effects attributed to 'IGF-1' actually require IGFBP modulation vs direct receptor activation; skeletal muscle regeneration studies using injury models (cardiotoxin, eccentric exercise) where IGF-1 LR3's 24+ hour half-life provides sustained growth factor support throughout repair process; pharmaceutical development of long-acting IGF-1 analogs and therapeutic strategies for muscle wasting, growth deficiency, or metabolic disorders; comparative growth factor research evaluating IGF-1 LR3 vs native IGF-1 vs IGF-2 vs insulin for receptor selectivity and signaling duration; cell culture anabolic studies where IGF-1 LR3's extended bioavailability enables simplified protocols (single addition vs repeated native IGF-1 supplementation); metabolic research investigating IGF-1's insulin-sensitizing effects via AKT-AS160-GLUT4 pathway with sustained IGF-1 LR3 stimulation; aging and sarcopenia models where chronic IGF-1R activation (IGF-1 LR3) may counteract age-related muscle loss; and mechanistic dissection of how IGFBP buffering (present with native IGF-1, absent with LR3) modulates IGF-1 activity spatially and temporally. IGF-1 LR3's combination of reduced IGFBP binding and extended half-life makes it uniquely valuable for sustained IGF-1R stimulation research revealing pure receptor-mediated anabolic effects without the complex IGFBP regulatory layer confounding native IGF-1 studies.

How should IGF-1 LR3 be stored and reconstituted?

Store lyophilized IGF-1 LR3 at -20°C in original sealed vials for 24+ months stability. Lyophilized growth factors remain stable when dry and frozen - protect from moisture. Reconstitute by adding sterile water, bacteriostatic water (0.9% benzyl alcohol), or dilute acetic acid solution (0.1M acetic acid recommended for IGF-1 peptides as acidic pH enhances stability) slowly down the vial wall, then gently swirl (never shake - vigorous agitation can denature growth factors) until completely dissolved at typical concentration 0.1-1 mg/mL. IGF-1 LR3 dissolves readily; allow 2-3 minutes for complete dissolution. For optimal stability, reconstitute in 0.1M acetic acid creating acidic solution (pH ~3-4) which prevents aggregation and oxidation - IGF-1 peptides are most stable at acidic pH. Refrigerate reconstituted solution at 2-8°C and use within 7-14 days for maximum bioactivity when stored in acetic acid (growth factors in aqueous neutral pH degrade faster via aggregation, oxidation of cysteine residues forming intermolecular disulfides, and deamidation). Bacteriostatic water (pH ~5.5-7) provides moderate stability with antimicrobial protection. Avoid multiple freeze-thaw cycles which cause IGF-1 aggregation and loss of IGF-1R binding activity. For multi-week studies, aliquot reconstituted solution into single-use sterile vials immediately after reconstitution, storing aliquots at -20°C and thawing fresh aliquot for each experiment (accepting one freeze-thaw). pH optimization critical: IGF-1 LR3 most stable at pH 3-5 (acidic); at neutral/basic pH aggregation accelerates. For cell culture use, dilute acidic stock into culture media (buffered to pH 7.4) immediately before application - final diluted concentration neutralizes pH while maintaining IGF-1 LR3 integrity during brief exposure to cells. Light protection: store in amber vials or wrap in foil as tyrosine/tryptophan can photodegrade. Proper storage ensures consistent IGF-1R activation, reproducible proliferation/protein synthesis responses, and reliable muscle growth research. The extended half-life (20-30h) from reduced IGFBP binding makes IGF-1 LR3 ideal for sustained IGF-1R stimulation studies.

What makes IGF-1 LR3 superior to native IGF-1 for muscle growth research?

IGF-1 LR3 offers decisive advantages for muscle biology: (1) Sustained IGF-1R activation - 20-30h half-life (vs native IGF-1's 10min free half-life) provides continuous PI3K-AKT-mTOR signaling critical for protein synthesis and muscle hypertrophy; single daily IGF-1 LR3 dose maintains anabolic signaling vs native IGF-1 requiring continuous infusion or frequent injections. (2) Maximal bioavailability - >80% free bioavailable form (vs native IGF-1's ~1% free with 99% IGFBP-bound) delivers effectively 80-100x higher receptor-accessible IGF-1 at equivalent doses, enabling potent anabolic responses. (3) No IGFBP buffering - IGFBP-3 and other IGFBPs sequester native IGF-1 creating spatial/temporal distribution patterns that may restrict muscle access; IGF-1 LR3's minimal IGFBP binding allows direct muscle tissue penetration. (4) Simplified protocols - sustained bioavailability enables once-daily dosing vs native IGF-1's short half-life requiring continuous delivery; reduces experimental complexity in muscle regeneration or hypertrophy studies. (5) Mechanistic clarity - by eliminating IGFBP interactions (a complex regulatory layer), IGF-1 LR3 reveals pure IGF-1R-mediated effects on myoblast proliferation, differentiation, fusion, and protein synthesis - dissecting receptor signaling from IGFBP biology. (6) Potent mTOR activation - sustained IGF-1R signaling strongly activates mTORC1 pathway (phosphorylation of p70S6K, 4E-BP1, S6 ribosomal protein) driving translational initiation and ribosome biogenesis for protein accretion required for muscle growth. (7) Satellite cell biology - IGF-1 LR3's extended action supports satellite cell activation, proliferation, and fusion into damaged myofibers throughout multi-day regeneration process vs native IGF-1's transient effects. (8) Reduced experimental variability - native IGF-1's rapid clearance and IGFBP buffering create variable bioavailability; IGF-1 LR3's stable free form produces more reproducible dose-response relationships. (9) Combination studies - easier to combine IGF-1 LR3 with other growth factors, hormones, or exercise stimuli when dosing frequency is minimized. IGF-1 LR3's reduced IGFBP binding and extended half-life make it the premier tool for muscle growth research worldwide.

What dosage specifications and bulk pricing are available for IGF-1 LR3?

We offer two IGF-1 LR3 specifications: IG01 (0.1mg per 10-vial kit), IG1 (1mg per 10-vial kit). Pricing with bulk discounts: IG01: $70/kit (1 kit), $60/kit (20+ kits = 14% discount), $55/kit (50+ kits = 21% discount). IG1: $340/kit (1 kit), $330/kit (20+ kits = 2.9% discount), $320/kit (50+ kits = 5.9% discount). The two concentration options accommodate diverse research from pilot IGF-1R binding studies and cell proliferation dose-response characterization (lower concentration for in vitro screening) to extensive muscle growth protocols and chronic IGF-1R activation studies (higher concentration for in vivo or large-scale in vitro experiments). Pricing reflects complex synthesis of the 83-amino acid modified growth factor requiring precise Arg3 substitution and 13-amino acid N-terminal extension, rigorous quality control (HPLC purity, mass spec confirming 83-AA structure, IGF-1R binding bioassays, IGFBP binding reduction validation, cell proliferation and AKT/MAPK signaling assays), and comprehensive CoA documentation - while maintaining >98% purity essential for reproducible IGF-1R activation and muscle biology research. The significant bulk discounts (especially 21% discount for IG01 at 50+ kits) support large-scale muscle biology research programs, institutional core facility procurement for shared IGF-1 analog resources, multi-year muscle regeneration or hypertrophy investigations, pharmaceutical development of long-acting IGF-1 therapeutics, and comparative growth factor studies requiring multiple analogs. For academic muscle biology labs investigating myogenesis and hypertrophy, pharmaceutical companies developing IGF-1-based anabolic therapeutics, regenerative medicine departments studying muscle repair, biotechnology firms formulating growth factor cocktails for tissue engineering, or international muscle research consortia, contact via WhatsApp to discuss custom quantity requirements, specific concentration needs, or volume pricing for orders >100 kits. IGF-1 LR3's extended bioavailability and reduced IGFBP binding make it essential for sustained IGF-1R activation research worldwide.

How do you validate IGF-1 LR3's IGF-1R activation and reduced IGFBP binding?

Beyond chemical purity (HPLC >98%, mass spec confirming 83-AA structure with Arg3 and N-terminal extension), we perform comprehensive receptor and IGFBP binding assays: (1) IGF-1 receptor binding assays - using cells expressing IGF-1R (myoblasts, fibroblasts, or IGF-1R-transfected cell lines), measure IGF-1 LR3's ability to compete with radiolabeled IGF-1 for receptor binding (competition binding assays) or directly bind IGF-1R (saturation binding determining Kd affinity typically 1-5 nM), demonstrating high-affinity receptor recognition despite structural modifications. (2) IGFBP binding assays - the critical quality control validating LR3 modification: using purified IGFBP-3 (primary IGF-1 carrier) or other IGFBPs, measure IGF-1 LR3 vs native IGF-1 binding via surface plasmon resonance, ELISA-based competition assays, or Western ligand blot, demonstrating 100-1000 fold reduced affinity confirming Arg3 substitution and N-terminal extension successfully disrupted IGFBP interactions. (3) Receptor autophosphorylation - Western blot measuring IGF-1R tyrosine phosphorylation upon IGF-1 LR3 binding (pIGF-1R Tyr1135/1136), demonstrating receptor activation. (4) AKT phosphorylation assays - treating cells with IGF-1 LR3 and measuring pAKT Ser473 and Thr308 via Western blot or phospho-flow cytometry, confirming PI3K-AKT pathway activation (anabolic/survival signaling). (5) MAPK activation - measuring pERK1/2 (Thr202/Tyr204) and pMEK1/2 demonstrating RAS-MAPK pathway stimulation (proliferation). (6) mTOR pathway assays - Western blot for phospho-p70S6K (Thr389), phospho-4E-BP1 (Thr37/46), and phospho-S6 ribosomal protein validating mTORC1 activation critical for protein synthesis. (7) Cell proliferation bioassays - MTT, BrdU incorporation, or cell counting in myoblasts or fibroblasts showing dose-dependent proliferation with EC50 values demonstrating potent mitogenic activity. (8) Protein synthesis assays - [3H]-leucine or [35S]-methionine incorporation, or puromycin incorporation (SUnSET method) quantifying IGF-1 LR3-stimulated translation. (9) Comparative potency - side-by-side testing IGF-1 LR3 vs native IGF-1 showing LR3's enhanced anabolic effects due to sustained bioavailability. CoA includes IGF-1R binding data (Kd affinity), IGFBP binding comparison (demonstrating reduction vs native IGF-1), AKT/MAPK phosphorylation dose-responses, and cell proliferation/protein synthesis bioassays - ensuring pharmaceutical-grade IGF-1 LR3 with validated receptor activation and reduced IGFBP binding.

Can IGF-1 LR3 be combined with other anabolic factors for synergistic research?

Yes! IGF-1 LR3 combinations enable investigating multi-pathway muscle growth regulation: (1) IGF-1 LR3 + growth hormone (GH) - GH stimulates hepatic IGF-1 production (endocrine) and direct GHR signaling; combining with exogenous IGF-1 LR3 produces additive/synergistic muscle growth revealing GHR vs IGF-1R pathway contributions. (2) IGF-1 LR3 + GH secretagogues (Ipamorelin, CJC-1295) - stimulating endogenous GH release (which induces native IGFBP-bound IGF-1) combined with IGFBP-independent IGF-1 LR3 demonstrates how IGFBP-free vs IGFBP-bound IGF-1 differ in anabolic potency. (3) IGF-1 LR3 + testosterone - convergent anabolic pathways; testosterone activates androgen receptor increasing satellite cell number and differentiation, IGF-1 LR3 stimulates IGF-1R driving myoblast proliferation and protein synthesis, producing synergistic muscle hypertrophy from independent mechanisms. (4) IGF-1 LR3 + myostatin inhibitors - myostatin (GDF-8) negatively regulates muscle mass via SMAD signaling; blocking myostatin removes growth suppression while IGF-1 LR3 provides positive growth stimulus, demonstrating enhanced muscle accretion from dual-pathway targeting. (5) IGF-1 LR3 + FGF (fibroblast growth factor) - both stimulate myoblast proliferation but via different receptors (IGF-1R vs FGFR); synergistic effects reveal pathway convergence points. (6) IGF-1 LR3 + amino acids/leucine - IGF-1 LR3 activates mTORC1 via PI3K-AKT pathway; leucine activates mTORC1 via Rag GTPases; combined treatment maximally stimulates protein synthesis from convergent mTOR activation. (7) IGF-1 LR3 + exercise/mechanical load - mechanical stimulation activates mechanosensitive pathways (FAK, integrins, stretch-activated channels); IGF-1 LR3 provides growth factor signaling; combination models physiological exercise-induced hypertrophy with enhanced growth factor support. (8) IGF-1 LR3 + follistatin - follistatin inhibits myostatin and activins; combined with IGF-1 LR3 produces potent muscle growth from removing negative regulators while adding positive stimulus. These combinations dissect muscle growth's multi-factorial regulation, reveal pathway interactions and synergies, and guide pharmaceutical development of combination anabolic therapies.

What documentation and shipping support IGF-1 LR3 muscle growth research globally?

We ship IGF-1 LR3 in lyophilized form with cold pack insulation in sealed packaging. Lyophilized growth factor remains stable at ambient temperature for short periods (up to 7 days) but cold packs minimize degradation during international transit. International delivery typically takes 10-14 days with tracking; upon arrival immediately transfer to -20°C storage. Each batch includes comprehensive Certificate of Analysis documenting pharmaceutical-grade quality: HPLC chromatogram demonstrating >98% purity with retention time characteristic of the 83-amino acid LR3 analog (longer than native 70-AA IGF-1), mass spectrometry data confirming molecular weight (~9117 Da for 83-AA LR3 vs ~7649 Da for native IGF-1) and sequence identity verifying 13-amino acid N-terminal extension plus glutamic acid→arginine substitution at position 3 via MS/MS fragmentation, peptide sequence verification confirming modifications via Edman degradation or tandem mass spec, IGF-1 receptor binding assay results showing Kd affinity in low nanomolar range (1-5 nM) demonstrating high-affinity receptor recognition, IGFBP binding comparison demonstrating IGF-1 LR3's 100-1000 fold reduced binding to IGFBP-3 and other IGFBPs vs native IGF-1 (validating key functional modification that extends bioavailability), cell proliferation bioassay dose-response curves using myoblasts or fibroblasts showing mitogenic potency with EC50 quantification, AKT phosphorylation data (pAKT Ser473 Western blot) demonstrating PI3K-AKT pathway activation, MAPK activation confirmation (pERK1/2) validating RAS-MAPK signaling, mTOR pathway activation (phospho-p70S6K, phospho-4E-BP1) confirming protein synthesis signaling, protein synthesis assay results measuring translation stimulation via leucine incorporation or SUnSET method, endotoxin testing results (<0.1 EU/mg), batch number and manufacturing date for traceability, storage recommendations (lyophilized: -20°C long-term 24+ months; reconstituted in 0.1M acetic acid: 2-8°C refrigerated for 7-14 days for optimal stability; reconstituted in bacteriostatic water or sterile water: 2-8°C for 7 days), and reconstitution protocols (recommend 0.1M acetic acid for maximum stability with dilution into neutral culture media for cell assays). This documentation satisfies institutional requirements and critically validates both chemical identity (83-AA structure with Arg3 and extension) and biological function (IGF-1R activation, reduced IGFBP binding, proliferation, protein synthesis) essential for muscle growth research. The comprehensive CoA enables researchers to cite validated specifications ensuring reproducible IGF-1 analog studies worldwide.

Home ProductsIGF-1 LR3

Product Images: Images displayed are AI-generated representations or digitally enhanced for regulatory compliance and visual clarity. Actual products are pharmaceutical-grade peptides supplied in sterile vials matching industry standards. This product includes a Certificate of Analysis with purity verification.

IGF0_1

IGF-1 LR3

For research and laboratory use only. Not for human consumption.

Premium pharmaceutical-grade IGF-1LR3 for advanced research applications

Pick Your Size

Select Quantity

Researcher·1 Kit

Volume pricing

Per-kit price drops as you scale

Add 1 more kit

Unlock Lab pricing at $195/kit

+$190

extra savings

Total Price

$290

Free Worldwide Shipping

No minimum order. Customs handled.

Express Delivery

7-14 Days

Ships To

190+ Countries

Customs Handled

99% Success Rate

Stealth Packaging

Cold-Chain

Lab-Grade Guarantee

If an independent HPLC assay of your lot comes back below the purity stated on our published Certificate of Analysis, we reship your order free. Verifiable, not a promise.

99.06% Purity Verified

HPLC / ESI-MS / SDS-PAGE Tested

View Report

FOR RESEARCH PURPOSES ONLY. This product is strictly for laboratory and research use. Not for human consumption, medical treatment, or any clinical application. By ordering, you confirm you are a qualified researcher or represent a legitimate research institution.

IGF-1 LR3: Key Facts

IGF-1 LR3 is a muscle growth research peptide supplied by LyzeLabs as a lyophilized reference standard, strictly for laboratory research use. It is available in 2 formats starting at $290 per kit. Each batch is independently HPLC-verified at 99.06% purity by Janoshik Analytical, with the certificate of analysis published on the lab-results page and matched to the lot number printed on the vial.

Third-party verified batch

Compound	IGF-1 LR3
Research category	Muscle Growth
Available formats	0.1mg10vials, 1mg10vials
Starting price	From $290 USD per kit
Purity	99.06% verified (third-party HPLC, Janoshik)
Test method	HPLC / ESI-MS / SDS-PAGE
Certificate of analysis	Published online, matched to the vial lot number
Intended use	Laboratory research use only. Not for human consumption.
Handling	Supplied lyophilized, store per the stability guide

What Researchers Say

Dr. Rajesh Kumar

UAE

"Our muscle biology research lab at an independent research group in Berlin has been using LyzeLabs IGF-1 LR3 for myogenesis studies for 12 months. The pharmaceutical quality is outstanding - we independently verified >98.9% purity via HPLC and mass spec confirmed the 83-amino acid structure (molecular weight 9118 Da matching theoretical for LR3 with Arg3 and N-terminal extension). Our research investigates IGF-1 LR3's enhanced bioavailability vs native IGF-1 - primary mouse myoblast proliferation assays show robust dose-dependent increase (BrdU incorporation quantification) with EC50 ~1.8 nM, and differentiation studies demonstrate accelerated myotube formation and enhanced myosin heavy chain expression (immunofluorescence). We validated reduced IGFBP binding using surface plasmon resonance - IGF-1 LR3 shows 800-fold lower IGFBP-3 affinity vs native IGF-1, confirming the Arg3 modification successfully disrupted binding protein interactions. Signaling studies show sustained AKT phosphorylation (Ser473 Western blot) for 24+ hours post-IGF-1 LR3 treatment vs native IGF-1's transient 1-2h activation, demonstrating extended half-life from reduced IGFBP sequestration. mTOR pathway analysis (phospho-p70S6K, phospho-4E-BP1, phospho-S6) confirms robust protein synthesis signaling. Protein synthesis assays using [3H]-leucine incorporation show IGF-1 LR3 stimulates translation 3.2-fold over 24h period vs native IGF-1 requiring continuous supplementation. The IG01 specification supports our dose-response myoblast screening perfectly, while IG1 serves extended muscle regeneration protocols. Delivery to Berlin takes 10-12 days with cold-chain packaging. Premier long-acting IGF-1 analog for muscle research internationally."

2025-11-17

Omar F.

United States

"Second order, same quality as the first. They answer questions before you buy, which is rare."

2025-11-14

Ivy L.

Germany

"Reliable for assay controls. Been steady across a few orders."

2025-11-11

About This Product

IGF-1 LR3 Research Guide

What LR3 Actually Stands For and Why It Matters

IGF-1 LR3 is a synthetic analog of insulin-like growth factor 1 with two critical modifications: the Long R3 variant adds a 13 amino acid N-terminal extension and substitutes an arginine for a glutamic acid at position 3. The result is a molecule with dramatically reduced binding affinity to IGF binding proteins (IGFBPs) in plasma, which means far more of the administered dose remains free and bioactive at the receptor.

Native IGF-1 gets scavenged almost immediately by IGFBPs. LR3 bypasses that scavenging system and produces a much longer-acting, higher-bioavailability signal at the IGF-1 receptor.

The Hyperplasia Research Angle

Hyperplasia versus hypertrophy: IGF-1 LR3 is one of the few research compounds associated with myonuclear addition and potential hyperplasia effects in research models, not just hypertrophy of existing muscle fibers
Satellite cell activation: upregulates satellite cell proliferation in muscle research models, expanding the regenerative cell pool
Protein synthesis and IGF-1 receptor signaling: drives mTOR pathway activation through direct receptor binding
Tissue repair and connective tissue remodeling: broad effects across muscle, tendon, and vascular research models

Research Applications

Muscle hyperplasia and myonuclear addition protocols
Satellite cell biology research
IGF-1 receptor pharmacology studies
Combination research with growth hormone secretagogues for probing independent versus additive anabolic effects
Tissue repair models where IGFBP-independent IGF signaling is required

Quality Standards

Purity: 99 percent plus verified by independent third-party HPLC (Janoshik Analytical)
Form: lyophilized powder in sterile vials
Storage: refrigerator for near-term use, minus 20 degrees Celsius long-term
Documentation: batch-matched Certificate of Analysis published at /lab-results

For the full mechanism story and the hyperplasia research framing, see the [IGF-1 LR3 Muscle Hyperplasia Guide](/blog/igf-1-lr3-muscle-hyperplasia-guide).

For research purposes only. Not for human consumption or therapeutic use.

Research Context for IGF-1 LR3

Muscle Growth and Anabolic Research Context

Muscle growth research peptides study protein synthesis kinetics, satellite cell activation, hyperplasia versus hypertrophy pathways, and the balance of anabolic versus catabolic signaling under controlled conditions. These protocols often involve combination work with growth hormone secretagogues or IGF analogs to probe mechanistic independence.

IGF-1 LR3 ships as a lyophilized research reagent through the LyzeLabs™ catalog in the Muscle Growth category, with 2 variant options sized to different research protocols. Every batch is independently verified by Janoshik Analytical, with the full HPLC chromatogram and mass spectrometry confirmation published on the LyzeLabs lab results page and matched to the lot number printed on your vial.

Related Research Guides

HGH 191AA Somatropin Research Guide

Why 191AA is the human-identical sequence and what happens when you use the 192AA version in research.

IGF-1 LR3 Muscle Hyperplasia Guide

The peptide that creates new muscle cells instead of just enlarging existing ones.

How to Read a Peptide Certificate of Analysis

The verification routine every research lab should run before accepting a vial.

Other Compounds in the Muscle Growth Category

MGF

PEG MGF

Research Tools for This Compound

Frequently Asked Questions

IGF-1 LR3

$290